EPICS: Global Perspectives in CAR T and Bispecific Agents in Hematologic Malignancies

Latest therapeutic developments in CAR T and bispecific agents in hematologic malignancies

August 26 and 31, 2022
Frederick Locke MD

Faculty Co-Chair

Frederick Locke, MD

H. Lee Moffitt Cancer Center

Faculty Co-Chair

Marie José Kersten, MD

Academic Medical Center

Faculty Members

Keith Stewart, MBChB, MBA
University Health Network

Jae Park, MD
Memorial Sloan Kettering Cancer Center

Paolo Caimi, MD
Case Western Reserve University School of Medicine

Peter Martin, MD
Weill Cornell Medicine

Irene Ghobrial, MD
Dana-Farber Cancer Institute

Daniel DeAngelo, MD, PhD
Dana-Farber Cancer Institute

Mohamad Mohty, MD, PhD
Saint-Antoine Hospital and Sorbonne University

Olivier Tournilhac, MD, PhD
Clermont Auvergne University

Josep-Maria Ribera, MD, PhD
Hospital Germans Trias i Pujol

Paolo Corradini, MD
Fondazione IRCCS Istituto Nazionale dei Tumori

Pier Luigi Zinzani, MD, PhD
University of Bologna Institute of Hematology and Medical Oncology

Sample Report

Start discovering the insights

View Report

REPORT TOPICS INCLUDE

  • Update on CAR T in DLBCL
  • Update on CAR T in Indolent NHL/MCL
  • Update on Bispecific Antibodies in B-NHL
  • Update on CAR T in Leukemias
  • Update on Bispecific Antibodies in Leukemias
  • Update on CAR T in MM
  • Update on Bispecific Antibodies in MM
  • Impact of Real-world Data on CAR T-Cell Therapies and Bispecific Antibodies
  • Sharing Experiences: Current Barriers to Real-world CAR T Adoption in the US
  • Sharing Experiences: Current Barriers to Real-world CAR T Adoption in Europe

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.